Jerry Conway, Senior Vice President of Market Access, joined GeneDx in January 2022 with over 30 years of sales and executive management experience in the routine clinical and esoteric laboratory marketplaces. His experience includes physician sales and marketing, payer contracting and reimbursement in a wide range of business environments, including Fortune 500 and start-up companies. Jerry was previously with Scipher Medicine, Diagnostics, Inc. and Foundation Medicine Inc. (FMI) in senior Market Access leadership roles. At FMI, Jerry was responsible for reimbursement of all diagnostic products, including the FDA-approved FoundationOneCDx universal companion diagnostic platform and National Coverage Determination (NCD) by CMS under the Parallel Review Program. Jerry also held senior Market Access Leadership roles with Metamark Genetics Inc., a national provider of cancer prognostic tests and services, and with Genzyme Genetics, a national provider of genetic health and oncology testing services. Under his leadership at Genzyme Genetics, Jerry helped to favorably position the company for a $975 million acquisition by Laboratory Corporation of America® Holdings on December 1, 2010. Prior to his career in market access and reimbursement, Jerry was employed by Damon Clinical Laboratories, Metpath/Corning and Long Term Care Services, Inc. in various diagnostic field sales and management roles in the physician and long term care markets.